Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Literature DB >> 21067392

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Tetsuya Tanimoto, Akiko Hori, Masahiro Kami.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2010 PMID： 21067392 DOI： 10.1056/NEJMc1009982

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

Keyword Cloud
Cited

× No keyword cloud information.

16 in total

1. Recent advances in the therapy of castration-resistant prostate cancer: the price of progress.

Authors: Dhwanishiva Vasani; David Y Josephson; Courtney Carmichael; Oliver Sartor; Sumanta Kumar Pal
Journal: Maturitas Date: 2011-08-09 Impact factor: 4.342

2. Bicalutamide 150 mg as secondary hormonal therapy for castration-resistant prostate cancer.

Authors: Su-bo Qian; Hai-bo Shen; Qi-feng Cao; Lin Zhang; Yi-fan Chen; Jun Qi
Journal: Int Urol Nephrol Date: 2015-02-10 Impact factor: 2.370

Review 3. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments.

Authors: H Inoue; K Tani
Journal: Cell Death Differ Date: 2013-07-05 Impact factor: 15.828

4. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.

Authors: Justin Guinney; Tao Wang; Teemu D Laajala; Kimberly Kanigel Winner; J Christopher Bare; Elias Chaibub Neto; Suleiman A Khan; Gopal Peddinti; Antti Airola; Tapio Pahikkala; Tuomas Mirtti; Thomas Yu; Brian M Bot; Liji Shen; Kald Abdallah; Thea Norman; Stephen Friend; Gustavo Stolovitzky; Howard Soule; Christopher J Sweeney; Charles J Ryan; Howard I Scher; Oliver Sartor; Yang Xie; Tero Aittokallio; Fang Liz Zhou; James C Costello
Journal: Lancet Oncol Date: 2016-11-16 Impact factor: 41.316

5. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.

Authors: Neha Kamran; Padma Kadiyala; Meghna Saxena; Marianela Candolfi; Youping Li; Mariela A Moreno-Ayala; Nicholas Raja; Diana Shah; Pedro R Lowenstein; Maria G Castro
Journal: Mol Ther Date: 2017-01-04 Impact factor: 11.454

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

1. Recent advances in the therapy of castration-resistant prostate cancer: the price of progress.

2. Bicalutamide 150 mg as secondary hormonal therapy for castration-resistant prostate cancer.

Review 3. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments.

4. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.

5. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.

6. Integrated Therapeutic Targeting of the Prostate Tumor Microenvironment.

7. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.

Review 8. Trial Watch: Anticancer radioimmunotherapy.

9. Oxibendazole inhibits prostate cancer cell growth.

Review 10. shRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapy.